Trading statement 9M 2024
07 Novembre 2024 - 7:59AM
UK Regulatory
Trading statement 9M 2024
Organic pro forma sales growth of 9%, including 11% in the third
quarter. Full-year organic sales growth outlook now expected at the
upper end of the 7-8% range and the adjusted EBITDA margin
confirmed between 35.5-36.5%.
Ester Baiget, President &
CEO: “We continue to execute strongly across the
business. Supportive, broad-based demand coupled with strong
innovation and commercial focus drive higher market penetration.
Novonesis’ biosolutions are increasingly requested by customers to
make their products and processes healthier and more efficient,
with less environmental impact. With 9% organic sales growth after
the first nine months, good realization of cost synergies and a
solid path to realize sales synergies, Novonesis is setting the
foundation for further value creation ahead.”
Pro forma sales
performance (9M comments unless otherwise
indicated)
Novonesis realized 9% pro forma organic sales growth for the first
9M 2024 (Q3 11%). Volumes increased ~7%, and pricing contributed
~2%. Pro forma sales amounted to EUR 2,964.1 million, an increase
of 6% (organic 9%, currency -2%, M&A -1%). Emerging markets
grew 14% organically, and developed markets increased 6%. Q3 sales
growth was strong and positively impacted by customers' order
timing.
- Food & Health Biosolutions realized pro
forma organic sales growth of 8% for 9M 2024 (Q3 11%). Pro forma
sales were EUR 1,337.1 million, an increase of 3% (organic 8%,
currency -2%, M&A -3% from the merger-related divestment of the
lactase enzyme business). Food & Beverages grew 9% (Q3 11%)
organically, and Human Health increased 3% (Q3 11%), in line with
expectations.
- Planetary Health Biosolutions realized pro
forma organic sales growth of 9% for 9M 2024 (Q3 12%). Pro forma
sales were EUR 1,627.0 million, an increase of 8% (organic 9%,
currency -1%). Household Care grew 15% (Q3 13%) organically and
Agriculture, Energy & Tech grew 7% (Q3 12%) organically.
Reported (IFRS) sales performance (Chr. Hansen included
as of January 29, 2024)
Novonesis reported 9% organic sales growth in 9M 2024 according to
IFRS reporting. Reported sales in EUR were 2,852.1 million (9M
2023: EUR 1,785.1) million). Please see Appendix 2 for further
details.
|
|
Pro forma |
Reported (IFRS) |
|
Organic sales growth, % |
9M 2024 |
9M 2023 |
Q3 2024 |
Q3 2023 |
9M 2024 |
9M 2023 |
Q3 2024 |
Q3 2023 |
|
|
|
|
|
|
|
|
|
|
|
Total sales |
9% |
6% |
11% |
8% |
9% |
5% |
11% |
8% |
|
|
|
|
|
|
|
|
|
|
|
Food & Health Biosolutions |
8% |
6% |
11% |
9% |
8% |
-2% |
11% |
7% |
| Food
& Beverages |
9% |
6% |
11% |
9% |
9% |
-1% |
11% |
7% |
| Human
Health |
3% |
6% |
11% |
8% |
6% |
-7% |
11% |
6% |
|
|
|
|
|
|
|
|
|
|
|
Planetary Health Biosolutions |
9% |
6% |
12% |
8% |
10% |
10% |
12% |
9% |
|
Household Care |
15% |
3% |
13% |
6% |
15% |
3% |
13% |
6% |
|
Agriculture, Energy & Tech |
7% |
8% |
12% |
8% |
7% |
19% |
12% |
11% |
|
|
|
|
|
|
|
|
|
|
2024 outlook*
Year-on-year, the second half of the year is
expected to grow stronger than the first half. The third quarter
sales growth was strong and benefitted from order timing. Following
this development, Novonesis now expects full-year organic sales
growth to be at the upper end of the 7-8% range, and the adjusted
EBITDA margin is confirmed to be between 35.5-36.5%. Both Food
& Health Biosolutions and Planetary Health Biosolutions are
expected to grow at around the same level as indicated for the
Group.
* The outlook 2024 is based on 12 months’
pro forma numbers for the consolidated business. The 2024 Reported
(IFRS) numbers for organic sales growth and adjusted EBITDA
margin are expected to be similar, i.e. the same
outlook. Refer to Company Announcement no. 21 – June 17, 2024, for
further details.
Please read the full announcement in PDF
- 2024_45_9M_2024_Company_Announcement
Grafico Azioni Novonesis AS (TG:NZM2)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Novonesis AS (TG:NZM2)
Storico
Da Dic 2023 a Dic 2024
